Pfizer is to set up an independent, stand-alone biotherapeutics and bioinnovation centre.
The firm said the centre’s remit would be to focus on discovering new medicines as well as securing new technologies and research tools that can be used across all Pfizer’s therapeutic areas.
The facility, to be located in the San Francisco Bay area of California, USA, is to be led neurobiologist Dr Corey Goodman.
Jeff Kindler, Pfizer’s chairman and chief executive officer, said the centre would benefit from “a unique structure to discover, license and acquire more new product candidates that we can put into development”.
He continued: “Corey Goodman will lead a centre that uses advanced applications of cell biology and cutting-edge technologies, sources the best science wherever we find it, and bridges the gap between basic research and drug discovery.”
The pharmaceutical giant also named Dr Martin Mackay as the new president of Pfizer Global Research and Development (PGRD).
Mr Kindler said: “As the leader of PGRD, Martin Mackay will bring Pfizer’s talent, drug discovery and development experience, capital and technology to bear on increasing the value of our near-term pipeline and bringing new compounds forward to approval.
“Martin will drive changes in PGRD’s goals, performance measurements, allocation of resources, culture and leadership so that Pfizer delivers a steady stream of new medicines that represent compelling value to our customers and payers.”
Copyright © PA Business 2007